Combining tocilizumab and atezolizumab for advanced lung cancer after previous treatments

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and effectiveness of tocilizumab in combination with atezolizumab for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not responded to prior immune checkpoint inhibitor therapy. Participants must have advanced non-squamous NSCLC and have received at least one line of therapy before enrolling. The study aims to determine how well this combination therapy works in this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
* Prior exposure to at least 1 line of therapy
* Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
* ECOG PS 0-2

Exclusion Criteria:

* Presence of a driver mutation that is susceptible to targeted therapy
* No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
* Other active invasive malignancy requiring ongoing therapy
* Evidence of progressing or untreated brain metastases
* Evidence or history of leptomeningeal disease
* Uncontrolled tumor related pain
* History of an autoimmune disease or IPF

Where it's running

• Abramson Cancer Center of the University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Melina Marmarelis, MD, MSCE — Abramson Cancer Center at Penn Medicine
• Study coordinator: Melissa Volpe, BA
• Email: melissa.volpe@pennmedicine.upenn.edu
• Phone: 215-220-9703

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Anticoagulation Plus Tocilizumab for Acute Cerebral Venous Thrombosis

  This study tests whether adding a single dose of tocilizumab to standard blood thinners helps people with acute cerebral venous thrombosis.

  Recruiting Capital Medical University · Beijing, Beijing Municipality · NCT07801638

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• BL-M14D1 with Atezolizumab for extensive-stage small cell lung cancer

  This phase 2 trial tests whether adding BL-M14D1 to atezolizumab helps people with extensive-stage small cell lung cancer live longer or well enough to continue treatment.

  Recruiting Phase 2 Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07654400

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• Linvoseltamab with pre-dose Tocilizumab to reduce CRS in adults with relapsed/refractory multiple myeloma

  This study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome in adults with relapsed/refractory multiple myeloma who have had at least four prior therapies.

  Recruiting at 7 sites Phase 4 Regeneron Pharmaceuticals · Los Angeles, California and 6 other locations · NCT07609940

• Preventing Cytokine Release Syndrome with a single dose of tocilizumab before ramantamig in multiple myeloma

  A single pre-treatment dose of tocilizumab is being tested to see if it can prevent or lessen cytokine release syndrome in people with relapsed or refractory multiple myeloma who are treated with ramantamig.

  Recruiting at 60 sites Phase 2 Janssen Research & Development, LLC · Goodyear, Arizona and 59 other locations · NCT07589634

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.